arrow_back Back Filing freshness 20-F FY 2025 SEC EDGAR

HUTCHMED (China) Ltd

HCM
$14.38 ▲ +0.29 (+2.02%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
13 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
59
Health
Fair
Bullish
auto_awesome

Analytical Summary

HUTCHMED (China) Ltd shows strong fundamentals with top-quartile Return on Common Equity (%) and Profit Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $12.3B
Dividend Yield —
Revenue Growth -13.0% ↗
Op. Margin -7.1% ↘
ROIC -2.3% ↗
FCF / Share $-0.09 ↘
Trailing P/E 27.1x
Price / Book 10.0x
FCF Yield —
Debt / Equity 0.10
info Valuation on last close. End-of-day price, Sep 23, 2026.

13-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$548.51M
↓ -13.0% —
Net Income Profit after all expenses
$456.91M
↑ +1111.0% —
Operating Margin Operating profit as % of sales
-7.1%
↓ -2.9% 18th
FCF / Share Free cash flow per share
$-0.09
↓ -350.4% —
Long-Term Debt Long-term obligations
$93.16M
↑ +12.5% —
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
  • Profit Margin (%)Profit Margin (%) is in the top quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↑
42
Returns
95
Financial Health ↑
54
Cash Quality
17

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 13 years · 13 quarters